lynne_bulger

Cipher appoints vice president and promotes two

pharmafile | January 26, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Linda Angaritis, Peter Weiler, cipher, lynne bulgar 

Cipher Pharmaceuticals has appointed Lynne Bulger as vice president of its medical and clinical affairs whilst also promoting Peter Weiler and Linda Angaritis to be VPs.

Bulger (pictured) has 27 years of experience in drug development in the pharma industry and joins the Canadian firm from Stiefel, a GSK company, where she held the position of director in medical affairs.

Previously Bulger was a director of medical and regulatory affairs at Barrier Therapeutics and a medical affairs director at Hoffman-La Roche. She also served as president of the Canadian Dermatology Industry Association from 2005 to 2008.

In addition to this appointment, Cipher has promoted Peter Weiler to the position of vice president within its business development unit, and Linda Angaritis as the VP of global regulatory compliance and quality.

Weiler has been with Cipher since 2008 and leads the company’s expanding business development activities. Angaritis joined in 2013 and is responsible for the overall regulatory compliance.

“We are pleased to welcome Lynne to Cipher’s management team,” says Shawn O’Brien, president and chief executive at Cipher. “I’d also like to congratulate Peter and Linda on their expanded roles with the organisation.”

Related Content

FDA issued the fewest warnings over pharma advertising this year since 1997

Throughout 2017, it has emerged that the FDA has issued a record low number of …

Latest content